TRVI Stock Analysis: Buy, Sell, or Hold?
TRVI - Trevi Therapeutics, Inc. Common Stock
$16.52
-1.32 (-7.40%)
▼
5d:
-7.97%
30d:
+23.28%
90d:
+25.25%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Smart Money Accumulation
None View Scanner →
Strength: 5.2/10
Get Alerted When TRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TRVI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TRVI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TRVI is currently trading at $16.52, which is considered fair relative to its 30-day fair value range of $14.51 to $18.53.
Technical Outlook: Technically, TRVI is in a strong uptrend. The price is currently testing key support at $16.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.90 (+44.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TRVI is in a strong uptrend. The price is currently testing key support at $16.52. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.90 (+44.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$14.51 -
$18.53
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
Protect Your Profits
Holding TRVI? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.4%)
- BULLISH: Trading 44.7% below Wall St target ($23.90)
- CAUTION: Recommendation downgraded due to -8.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$14.51 -
$18.53
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$16.52
Resistance Level
$20.15
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.62
Wall Street Target
$23.90
(+44.7%)
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
Advanced TRVI Option Strategies
Professional options setups generated by AI based on today's TRVI price and gamma walls.
